VBI Vaccines Inc. - Special Call Transcript
Great. It looks like attendees are filing in, and the queue has slowed down. So I just want to say good morning, and thank you, everyone, for joining us for today's fireside chat with VBI Vaccines to discuss the company's hepatitis B portfolio. I'm Steve Seedhouse, research analyst at Raymond James. I'll be hosting today's event.
By way of background, we've covered VBI for over a year. And we've been recommending to stock on the basis of their promising therapeutic and prophylactic vaccine platform, with the company advancing towards U.S. and European approvals and launch of Sci-B-Vac, a prophylactic hepatitis B or HBV vaccine next year potentially as well as numerous announcements the company has made in recent weeks that we'll discuss over the next 30 or 40 minutes. It's a timely conversation.
To start, I'd like to invite CEO, Jeff Baxter, to provide a brief slide presentation, which is available, by the way, over Zoom for those that may be dialing in by phone, to review the hepatitis B
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
